Delta-tocotrienol augments cisplatin-induced suppression of non-small cell lung cancer cells via inhibition of the Notch-1 pathway

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2647-2656

  Ji, Xiangming ^a   Wang, Zhiwei ^b   Sarkar, Fazlul H ^b   Gupta, Smiti V ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A160 cells; A549; Apoptosis; Cisplatin; Delta tocotrienol; Non small cell lung carcinoma; Notch 1

Indexed keywords

ALPHA TOCOTRIENOL; CASPASE 3; CISPLATIN; DELTA TOCOTRIENOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH1 RECEPTOR; PROTEIN BCL 2; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; VITAMIN E;

EID: 84865699135     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA et al: MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol 4: 1028-1034, 2009.
3. Chrysogelos SA and Dickson RB: EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 29: 29-40, 1994. (Pubitemid 24104835)
4. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM et al: EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 107: 247-258, 2002.
5. Artavanis-Tsakonas S, Rand MD, Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284: 770-776, 1999. (Pubitemid 29291335)
6. Buchler P, Gazdhar A, Schubert M, Giese N, Reber HA, Hines OJ et al: The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg 242: 791-800, discussion 800-791, 2005.
7. Lin JT, Chen MK, Yeh KT, Chang CS, Chang TH, Lin CY et al: Association of High Levels of Jagged-1 and Notch-1 Expression with Poor Prognosis in Head and Neck Cancer. Ann Surg Oncol 2010.
8. Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson BC et al: Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol 33: 1223-1229, 2008.
9. Westhoff B, Colaluca IN, D'Ario G, Donzelli M, Tosoni D, Volorio S et al: Alterations of the Notch pathway in lung cancer. PNAS 106: 22293-22298, 2009.
10. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H and Dorken B: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99: 3398-3403, 2002. (Pubitemid 34525322)
11. Miele L and Osborne B: Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol 181: 393-409, 1999. (Pubitemid 29513408)
12. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D et al: American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27: 3235-3258, 2009.
13. Stordal B, Davey M: Understanding cisplatin resistance using cellular models. IUBMB Life 59: 696-699, 2007. (Pubitemid 350035586)
14. Zhang ZP, Sun YL, Fu L, Gu F, Zhang L and Hao XS: Correlation of Notch1 expression and activation to cisplatin-sensitivity of head and neck squamous cell carcinoma. Ai Zheng 28: 100-103, 2009.
15. Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L et al: Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 23: 671-676, 2010.
16. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320, 2008.
17. Aleksic T and Feller SM: Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells. Cell Commun Signal 6: 8, 2008.
18. Ji X, Wang Z, Geamanu A, Sarkar FH, Gupta SV: Inhibition of cell growth and induction of apoptosis in non-small cell lung cancer cells by delta-tocotrienol is associated with notch-1 down-regulation. J Cell Biochem 112: 2773-2783, 2011.
19. Wang Z, Zhang Y, Banerjee S, Li Y and Sarkar FH: Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106: 2503-2513, 2006. (Pubitemid 43787677)
20. Watanabe K, Inai S, Jinnouchi K, Bada S, Hess A, Michel O et al: Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res 22: 4081-4085, 2002. (Pubitemid 36134437)
21. Lee JE, Nakagawa T, Kita T, Kim TS, Iguchi F, Endo T et al: Mechanisms of apoptosis induced by cisplatin in marginal cells in mouse stria vascularis. ORL J Otorhinolaryngol Relat Spec 66: 111-118, 2004. (Pubitemid 39194336)
22. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
23. Itoh M, Fu L and Tohda S: NF-kappaB activation induced by Notch ligand stimulation in acute myeloid leukemia cells. Oncol Rep 22: 631-634, 2009.
24. Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE et al: Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J 25: 129-138, 2006. (Pubitemid 43077302)
25. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J et al: The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 18: 268-281, 2010.
26. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O and Sarkar FH: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65: 6934-6942, 2005. (Pubitemid 41060733)
27. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ et al: Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65: 9064-9072, 2005. (Pubitemid 41377399)
28. Shibata A, Nakagawa K, Sookwong P, Tsuduki T, Tomita S, Shirakawa H et al: Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxia-inducible factor-1alpha. J Nutr 138: 2136-2142, 2008.